Comprehensive Decision Making Intelligence derived from Active 931 Oncology Drug Developers. OI 2014 is a key update over previous report OI 2013, as it covers 398 more oncology drug developers than the previous report. It also abandoned 91 companies, which were earlier covered in OI 2013, which were either acquired/merged or closed during the period. For Details Visit - https://omicsx.com/reports/cancer/oncology-intelligence-report-2014/

1. 2014Oncology Intelligence
A Comprehensive Report for Decision Making
Second Edition

2. most
updated
information
REPORT CONTAINS
931
Cancer
Companies
360
Cancer preclinical
Pipeline
Companies
2237
Molecules in
Clinical
Trials
Oncology Intelligence
A Comprenehsive Report for Decision Making 2014
4264+
Indications
In Trials
228+
Cancer
Targets
900+
523
Cancer Clinical
Companies
Updates
Interactive 1055+ pages, divided into 6 Sections, with Infographics and Tables
Late-
Preclinical
Molecules

3. Worldwide Distribution of Oncology focused companies, with active clinical pipeline.
Division of Companies on the Basis of Market/Assets Valuation and
Ownership, along with their country wise distribution.
Division of Cancer Companies on the basis of employee numbers
and Year of Incorporation.
Distribution of Cancer Companies within United States of America.
Helps in identifying the research incubating countries.
ALL INFOGRAPHICS PAGES 931 COMPANIES Total 6 Pages with 14 Figures and 1 Table
Helps in identifying cancer research trends among Small, Mid & Large companies
also as Public, Private & Subsidiaries, with nation wise preferences for the sector.
Helps in understanding cancer research funding needs (employee size states the
economic dependency of company) and emergence of Cancer Drug Discovery Sector
going ahead (with pace of new companies/assets are entering in clinical trials).
Helps in identifying the cancer research hubs and research supporting states.

4. Few Sample Pages of Section A

5. Worldwide Distribution of cancer targeting molecules in clinical development.
Helps in identifying the emerging trends between Small molecules Vs. Biologics.
PAGES CONTAINS INFOGRAPHICS & TABLES 2237 MOLECULES & 228 TARGETS Total 63 Pages with Figures & Tables
Molecule Developing Strategies - Top 10 Companies.
Helps to explore how the Big Pharma drug strategies are changing (by comparing molecules
from Ph III to Ph I), and what others companies are pursuing.
Protein Kinases Inhibitors Development Strategies – Top 10 Vs. Others.
Cancer Drug Targets – Established Vs. Emerging Targets.
Key focus of Report, helps in clearly identifying emerging targets. Covers 228+ targets with their
complete details, research findings w.r.t cancer and drugs under development for each target.
Established Protein Targets Vs emerging protein kinases- development profiles. Know
more which companies are more focusing on PK and for which cancer indications.
Cancer Drugs in Development – mAbs , Vaccines, mAbs-drug conjugates
Gene Therapies & description of various others molecules.

6. Page 2 & 3, shown above contains cuttings of various pages. For more details, kindly refer Table of Contents.
Few Sample Pages of Section B

7. Division of total drug Indications among top 19 cancer subtypes (like Lung, Breast, Melanoma, etc.)
Helps in identifying the emerging vs. current Cancer Indications.
PAGES CONTAINS INFOGRAPHICS & TABLES 4264 DRUG INDICATIONS in 19 CANCER TYPES Total 95 Pages with Figures & Tables
Phase wise & Region wise, Distribution of Drug Indications.
Exploring ‘who’ is developing ‘what’?
Cancer Indications Development Strategies - Top 10 companies Vs. others.
Identifying the emerging cancer subtypes of interest among Big Pharma and their choice
towards development of small/biologics.
Complete Clinical Drug Development Profiles of 19 Cancer Subtypes.
Identifying the emerging Vs. underserved cancer subtype.
First Report which equally focuses underserved cancer subtypes.
Orphan Drug Status molecules and their cancer indications (USFDA & EMEA).
Oncology Clinical Pipeline –Major Advances/Failures & New Entrants - 2013.

8. Above Infographic s are the part of Report . For more details, kindly refer Table of Contents.
Few Sample Pages of Section C

9. Focused profiles of 532 individual cancer companies, with active clinical pipeline.
Companies having active clinical trials, with development & marketing rights of molecules in cancer treatment
are only included. No company with dead assets (trials-status unknown/last updated prior 2010) are included.
PAGES CONTAINS 523 COMPANIES PROFILES Total 598 Pages
Profiles are written as mini-report for an individual company.
All Inferences are derived in this report in earlier sections are based on these
mini companies’ reports, thus the report validates itself.
Profile contains Company’s key management, key oncology assets (both clinical & preclinical), key
collaborations, Investors, Molecules profile, their targets & development strategies etc.
No Information is Duplicated.
The strongest point of Report, beside been precise is that, no information is
duplicated anywhere, that helps to avoid confusions/errors.
Only Oncology focused events are documented, to avoid any ambiguous data.

10. Company Profile Pages – Merck Serono
Oncology focused :- Key
Highlights of Company, Key
technology, Collaborations,
partners, Approved pipeline, etc.
Cancer Targeted Molecules in
Clinical Development:-
Molecule name(s), Target, Clinical
Phase, all possible Indications of
development of the molecule,
Last Updated on Clinical Trials
with Trial Status as on Dec 2012 &
Drug type (Small/Biologic/NBCM).
Key Highlights of Drugs in
Development :- Drug’s Target
Description, Mechanism of
Action, Orphan Status, Preclinical
Pipeline etc.Management Profile: Contact Address, Founded Year, Ownership,
Key Management People, Stock Ticker and Market Capitalization

11. Focused profiles of individual cancer companies, with active preclinical pipeline.
Companies with molecules in late preclinical development for cancer treatment.
PAGES CONTAINS 360 COMPANIES PROFILES Total 215 Pages
Exclusive focus on Partnering and Emerging Proprietary Technology.
Covers 900+ molecules in preclinical development.
Only Late Preclinical Pipeline companies are included.
Reports covers 900+ disclosed Preclinical Molecules in development by both clinical
and preclinical companies.
No Exclusive Cancer Discovery Phase or Lead Optimization Companies are covered to
avoid ambiguity.
Cancer Companies Profiles are in form of Mini-Reports.
Covers Management profile, Key Investors, Key Technology Partners, pipeline
description etc.

12. For more details, kindly refer Table of Contents.Few Sample Pages of Section F
Key Technology Platform.
Key Technology Partners,
Key Investors & other Company
and Cancer Drug Highlights.
Preclinical Pipeline Details with
Targets and Indications Detail.
Key Technology Platform.
Key Technology Partners,
Key Investors & other Company
and Cancer Drug Highlights.